Related Experiment Videos
Antibody response to pneumococcal vaccine in children aged 5 to 15 years
Insights
Children aged 8-10 showed a plateau in pneumococcal antibody response, while older children (13-15) had improved responses to certain serotypes. Antibody levels were similar in healthy children and those with hematologic disorders.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- Pneumococcal infections pose a significant threat to children's health.
- Understanding age-related antibody responses to pneumococcal vaccines is crucial for optimizing immunization strategies.
- The impact of hematologic disorders and splenectomy on vaccine response requires further investigation.
Purpose of the Study:
- To analyze the type-specific antibody response to a 14-valent pneumococcal vaccine in healthy children aged 5-15 years.
- To compare the antibody response in healthy children with that of children suffering from hematologic disorders.
- To determine the influence of age on pneumococcal antibody production.
Main Methods:
- Quantified type-specific antibody responses in 99 healthy children (5-15 years) post-vaccination.
- Analyzed antibody levels based on age at vaccination.
- Compared antibody responses between healthy children and 23 children with hematologic disorders (12 splenectomized).
Main Results:
- Antibody response to most pneumococcal serotypes, including pediatric types 6A, 18C, and 19F, plateaued in children aged 8-10 years.
- For serotypes 14 and 23F, antibody response continued to increase up to ages 13-15 years.
- No significant difference in antibody response was observed between healthy children and those with hematologic disorders.
Conclusions:
- Age significantly influences the antibody response to specific pneumococcal serotypes in children.
- Children with hematologic disorders, including those who have undergone splenectomy, exhibit similar pneumococcal antibody responses compared to healthy children.
- These findings contribute to understanding pneumococcal vaccine efficacy across different pediatric age groups and health statuses.
Abstract:
The type-specific antibody response of 99 healthy children, aged 5 to 15 years, to a 14-valent pneumococcal vaccine was determined and analyzed according to age at the time of vaccination. The response to the majority of the serotypes, including the important "pediatric" types 6A, 18C, and 19F, appeared to plateau in the 8- to 10-year-old age group, whereas for types 14 and 23F, which are also important in children, the response continued to improve with age to ages 13 to 15 years. The antibody response of a group of 23 children, aged 5 to 15 years, with various hematologic disorders (12 of whom had undergone splenectomy) was also determined and compared with that of the healthy children. For all serotypes the antibody response was similar in the two groups.